⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARTV News
Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
globenewswire.com
ARTV
The $13 Million Company Teaching the Immune System to Hunt Cancer
prnewswire.com
NKTX
GTBP
IBRX
FATE
ARTV
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
globenewswire.com
ARTV
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
globenewswire.com
ARTV
Form 8-K
sec.gov
ARTV
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
globenewswire.com
ARTV
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
prnewswire.com
GTBP
ARTV
FATE
IBRX
CHRS
Form 8-K
sec.gov
ARTV
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
ARTV
Form 8-K
sec.gov
ARTV